• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

    1/8/24 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email

    EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023.

    "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated Mr. Wyszomierski.

    "I am grateful for the opportunity to lead XOMA as we look to solidify our position as a leading capital provider to emerging biotech companies," stated Mr. Hughes.  "Our growing cash receipts and maturing portfolio reflect the inherent opportunity for significant inflection points within XOMA's established royalty and milestone acquisition strategy.  I am committed to ensuring XOMA stockholders benefit from our disciplined and effective capital deployment strategy, which today is bolstered by the largest cash balance in XOMA's history."

    About Owen Hughes

    Owen Hughes has spent the last 25 years in the healthcare field as both an operator and an investor.  He has served as the Chief Executive Officer of Sail Bio, Inc., Chief Executive Officer and Co-founder of Cullinan Oncology, and Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc.  Prior to his operational roles, Mr. Hughes served as a Director at Bain Capital, LP, and Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments Company.  He currently serves as the Chairman of the Board of Directors of Ikena Oncology, a member of the Board of Directors for C4 Therapeutics, and previously served as the Chairman of Radius Health and the Lead Independent Director of Translate Bio until their sales to Gurnet Point Capital and Sanofi, respectively.  Mr. Hughes holds a B.A. in history from Dartmouth College.

    About Jack Wyszomierski

    Jack Wyszomierski has been a director of XOMA since August 2010 and Lead Independent Director since May 2023.  From 2004 until his retirement in 2009, Mr. Wyszomierski was Executive Vice President and Chief Financial Officer of VWR International, LLC, a global laboratory supply, equipment and distribution business that serves the world's pharmaceutical and biotechnology companies, as well as industrial and governmental organizations.  At Schering-Plough, a global health care company which had worldwide sales of over $8 billion in 2004, Mr. Wyszomierski held positions of increasing responsibility from 1982 to 2004 culminating in his appointment as Executive Vice President and Chief Financial Officer.  Mr. Wyszomierski also serves on the Board of Directors of Athersys, Inc., Exelixis, Inc. and SiteOne Landscape Supply, Inc., and previously served on the Board of Directors of Unigene Laboratories, Inc., from 2012 to 2013.  He holds an M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University.

    About XOMA Corporation

    XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

    Forward-Looking Statements/Explanatory Notes

    Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential expansion and accelerated growth of XOMA's portfolio and the potential for this portfolio to generate sustained cashflows and positive returns over time.  In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will", "would," "could" or "should," the negative of these terms or similar expressions.  These forward-looking statements are not a guarantee of XOMA's performance, and you should not place undue reliance on such statements.  These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic.  Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission.  Consider such risks carefully when considering XOMA's prospects.  Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

    EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

    As of the date of this press release, all assets in XOMA's milestone and royalty portfolio, except VABYSMO® (faricimab) and IXINITY® [coagulation factor IX (recombinant)], are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

    XOMA Investor ContactXOMA Media Contact
    Juliane SnowdenKathy Vincent
    XOMA CorporationKV Consulting & Management
    +1 646-438-9754+1 310-403-8951
    [email protected][email protected]


    Primary Logo

    Get the next $XOMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Financials

    Live finance-specific insights

    See more
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

      3/20/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about January 15, 2025, to respective holders

      12/19/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    SEC Filings

    See more

    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form DEF 14A filed by XOMA Royalty Corporation

      DEF 14A - XOMA Royalty Corp (0000791908) (Filer)

      4/15/25 4:30:48 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by XOMA Royalty Corporation

      PRE 14A - XOMA Royalty Corp (0000791908) (Filer)

      4/4/25 4:30:37 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by XOMA Royalty Corporation

      10-K - XOMA Royalty Corp (0000791908) (Filer)

      3/17/25 4:45:58 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/24 10:05:21 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

      SC 13D/A - XOMA Corp (0000791908) (Subject)

      1/16/24 5:22:40 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/23 12:46:50 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

      The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

      4/17/25 8:34:06 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on XOMA with a new price target

      Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

      4/29/24 8:01:47 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on XOMA with a new price target

      HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

      10/8/21 6:18:28 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

      EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET.  

      5/7/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

      EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (("XOMA", NASDAQ:XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025. Mr. Sitko's presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT.  The presentation can be assessed by visiting https://bit.ly/4l7bz6m. XOMA's presentations can also be accessed by visiting the investor relations section of the Company's website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event. A

      4/2/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Leadership Updates

    Live Leadership Updates

    See more
    • XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

      Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

      5/9/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

      EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated

      1/8/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care